Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

InMed Pharmaceuticals — 14 videos in collection

More on this equity

In this video, InMed CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN clearly demonstrated the most optimal effect for glaucoma over other cannabinoids.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free